Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMA

Castle’s interface with EMA is expected to be complete by year-end 2021.

Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 

The interface is designed to enable dermatologic clinicians to order Castle’s DecisionDx skin cancer tests from directly within a patient’s medical record in EMA.

“At Castle, we are excited to facilitate the ordering of our skin cancer portfolio from directly within one of the most widely utilized dermatologic electronic health records systems, EMA,” says Toby Juvenal, chief commercial officer of Castle Biosciences, in a news release. “We are committed to impacting patient care, and our diagnostic tests are designed to provide clinically-actionable information to clinicians and patients to inform disease management decisions. The EMA platform has been ranked #1 by dermatologists for the past eight years by Black Book. Our interface with this system is expected to streamline the ordering process and allow for delivery of Castle’s test results within the system.”

Castle’s full suite of skin cancer tests will be available to order within EMA: DecisionDx-Melanoma for cutaneous melanoma, DecisionDx-SCC for cutaneous squamous cell carcinoma and the Company’s Comprehensive Diagnostic Offering for difficult-to-diagnose melanocytic lesions (comprised of myPath Melanoma and DecisionDx DiffDx-Melanoma).